TOP > 外国特許検索 > OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE

OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE

外国特許コード F170008931
整理番号 (S2015-0845-N0)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP059398
国際公開番号 WO 2016152980
国際出願日 平成28年3月24日(2016.3.24)
国際公開日 平成28年9月29日(2016.9.29)
優先権データ
  • 特願2015-060689 (2015.3.24) JP
発明の名称 (英語) OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE
発明の概要(英語) [Problem] To provide a novel oligonucleotide derivative that is easy to synthesize and can be introduced into cells without using a lipofection reagent. [Solution] The oligonucleotide derivative of the present invention is shown by, e.g., (1). This derivative is considered to bind an aminoglycan moiety to a ligand on the surface of a cell and be introduced into the cell, and can be expected to have selective drug delivery functions. In the formula, R1 and R2 each independently represent a hydrogen or phosphate group; a, b, and c independently represent integers of 0 or higher, at least one of a, b, and c being 1 or higher; A and B independently represent optionally modified oligonucleotides having a combined chain length of A and B of 3 or higher. However, A and B do not include hydroxyl groups at the 3' end and 5' end of the oligonucleotide. Furthermore, S in the formula indicates a sugar substituent, a peptide chain, or a tocopherol binding group. Additionally, an alkyl group may be bonded, in lieu of hydrogen, to the benzene ring in the formula.
特許請求の範囲(英語) [claim1]
1. The next formula the [origonukureochido] derivative which is displayed with (1).
[claim2]
2. The next formula the [origonukureochido] derivative which is displayed with (2).
[claim3]
3. The description above S the below-mentioned chemical structure formula (3) or (3 ') with in the claim 1 which is shown or 2 the [origonukureochido] derivative of statement.
[claim4]
4. The [origonukureochido] derivative which is displayed with the next formula.
[claim5]
5. R (1) and R as for (2) the claim either 1 which features that it is H or 4 in 1 sections the [origonukureochido] derivative of statement.
[claim6]
6. As for B 0 the claim either 1 which features that is or 5 in 1 sections the [origonukureochido] derivative of statement.
[claim7]
7. A and b together 0 the claim either 1 which features that is or 6 in 1 sections the [origonukureochido] derivative of statement.
[claim8]
8. As for C in the claim 7 which features that it is 5 or less of 1 or more the [origonukureochido] derivative of statement.
[claim9]
9. A and as for B, the claim either 1 which possesses the part arrangement or that complimentary arrangement of specified gene mRNA or 8 in 1 sections the [origonukureochido] derivative of statement.
[claim10]
10. A and as for the chain length which adjusts B, the claim either 1 which is 35 or less of 10 or more or 9 in 1 sections the [origonukureochido] derivative of statement.
[claim11]
11. A and as for B the claim either 1 which features that it is [origoribonukureochido] or 10 in 1 sections the [origonukureochido] derivative of statement.
[claim12]
12. Being [origonukureochido] construction ones of gene revelation adjustment,
Claim either 1 or 11 construction ones which possess the [origonukureochido] derivative of statement in 1 sections.
[claim13]
13. 1 these chains and 2 these chains DNA, 1 these chains and 2 these chains RNA, being [origonukureochido] construction ones of gene revelation adjustment which are selected from the DNA/RNA chimera and the DNA/RNA hybrid, in claim 12 construction ones of statement.
[claim14]
14. In the claim 12 which is selected from [anchijin], anti sense, [aputama], siRNA, miRNA, shRNA and [ripozaimu] or 13 construction ones of statement.
[claim15]
15. In the dangling ended part formula below the claim either 12 which possesses the unit which is displayed with (4) or (5) or 14 construction ones of 1 section statements.
[claim16]
16. Being SiRNA, a and b 0 are in the aforementioned [origonukureochido] derivative, construction ones of the claim 15 statement which includes the unit where c is, 1 or 2 3' in the terminal dangling ended part formula below is displayed with (4) or (5).
[claim17]
17. Being [origonukureochido] construction ones of gene diagnosis, claim construction ones where has the [origonukureochido] derivative of statement in either 1 or 11.
[claim18]
18. In the claim 17 which features that it is the probe construction ones of statement.
[claim19]
19. Formula below (6) or (7) with the chemical compound which is displayed.
[claim20]
20. In the claim 19 which is for dangling ended unit of SiRNA the chemical compound of statement.
[claim21]
21. Decoration method of [origonukureochido] which features that 1 kinds or 2 kinds or more which are selected to claim 19 from the chemical compound of statement are used.
[claim22]
22. Decoration method of [origonukureochido] which features that at least the formula 1 or less it adds the unit which is displayed with (4) or (5) to [origonukureochido], it introduces either substitution and insertion or combining these.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • GIFU UNIVERSITY
  • 発明者(英語)
  • KITADE YUKIO
  • SHIBATA AYA
国際特許分類(IPC)
指定国 (WO2016152980)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
岐阜大学産官学連携推進本部では、岐阜大学における知的財産の創出・管理・活用のマネジメントをしています。上記の特許・技術に関心のある方は、下記問い合わせ先に整理番号とともにご相談下さい。

PAGE TOP

close
close
close
close
close
close